Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + trametinib versus vemurafenib in BRAF V600E/K mutation-positive advanced cutaneous melanoma
2011-006088-23Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cutaneous melanoma (CM) and melanoma comparing dabrafenib + trametinib with vemurafenib (2 arms). Primary endpoint: overall survival. Started Apr 2012; status: completed.
02
Drugs
dabrafenib + trametinibtrametinibvemurafenib
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2011-006088-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006088-23.